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ABSTRACT
Most genome-wide association studies (GWAS) were analyzed using single marker 
tests in combination with stringent correction procedures for multiple testing. Thus, a 
substantial proportion of associated single nucleotide polymorphisms (SNPs) remained 
undetected and may account for missing heritability in complex traits. Model selection 
procedures present a powerful alternative to identify associated SNPs in high-dimensional 
settings. In this GWAS including 1060 colorectal cancer cases, 689 cases of advanced 
colorectal adenomas and 4367 controls we pursued a dual approach to investigate genome-
wide associations with disease risk applying both, single marker analysis and model 
selection based on the modified Bayesian information criterion, mBIC2, implemented 
in the software package MOSGWA. For different case-control comparisons, we report 
models including between 1-14 candidate SNPs. A genome-wide significant association of 
rs17659990 (P=5.43×10-9, DOCK3, chromosome 3p21.2) with colorectal cancer risk was 
observed. Furthermore, 56 SNPs known to influence susceptibility to colorectal cancer 
and advanced adenoma were tested in a hypothesis-driven approach and several of them 
were found to be relevant in our Austrian cohort. After correction for multiple testing 
(α=8.9×10-4), the most significant associations were observed for SNPs rs10505477 
(P=6.08×10-4) and rs6983267 (P=7.35×10-4) of CASC8, rs3802842 (P=8.98×10-5, 
COLCA1,2), and rs12953717 (P=4.64×10-4, SMAD7). All previously unreported SNPs 
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demand replication in additional samples. Reanalysis of existing GWAS datasets using 
model selection as tool to detect SNPs associated with a complex trait may present a 
promising resource to identify further genetic risk variants not only for colorectal cancer.
INTRODUCTION
Numerous genome-wide association studies 
(GWAS) in diverse complex diseases have uncovered 
hundreds of genetic risk factors by determining hundred 
thousands of single nucleotide polymorphisms (SNPs) 
in cohorts of thousands of individuals in a hypothesis-
free approach. Although these findings provide valuable 
insights into the genetic architecture of common diseases 
they collectively account for a relatively small proportion 
of heritability [1].
Colorectal carcinogenesis is a complex multi-step 
process influenced by both, genetic and environmental 
risk factors. Only 5-10% [2] of all colorectal cancer 
(CRC) cases can be ascribed to hereditary syndromes and 
explained by rare but high-penetrant germline mutations. 
Another 30% of CRCs can be attributed to non-syndromic 
familial cases with increased familial risk but without 
evidence of predisposing mutations. The remaining CRCs 
evolve sporadically and are influenced by numerous genetic 
variants with low penetrance but of high prevalence in the 
population (>1%). This common disease-common variant 
hypothesis was formulated in the early days of GWAS, 
but was relativized when identified risk loci explained 
only a small fraction of genetic variance in complex traits. 
More refined concepts include the common disease-rare 
variant hypothesis [2], the infinitesimal and the broad sense 
heritability model (discussed in [3]).
GWAS of CRC conducted in European but also 
Asian populations have discovered so far more than 50 risk 
variants [4–29] mapping to 23 susceptibility loci. Although 
GWAS have successfully identified multiple associations 
of genetic variants with risk of CRC, collectively the CRC 
SNPs identified in European populations account only for 
8% of familial CRC risk [30]. Additional rare risk variants 
still remain undetected and in part may account for the 
missing heritability of CRC.
Typically, GWAS aims at the identification of a 
relatively small set of SNPs associated with the investigated 
phenotype. SNPs exceeding a genome-wide significance 
threshold (P < 5×10-8) are tested for replication in 
independent samples. Inevitably, these necessarily stringent 
penalties for multiple testing have the consequence that a 
relatively large proportion of associated SNPs cannot be 
detected. Consequently, the majority of missing heritability 
may be due to SNPs with effects below the level of genome-
wide significant associations [3].
The vast majority of GWAS have been analyzed via 
single marker analysis. One advantage of this approach is 
its computational inexpensiveness. However, this standard 
approach to analyze association with disease risk for each 
SNP individually assumes complete independence of 
the analyzed SNPs [31]. In contrast, genetic risk often 
can be explained as the influence of multiple SNPs 
mapping to various chromosomal regions resulting in a 
phenotype [32]. Furthermore, single marker tests cannot 
take into consideration the distinct correlation structure 
among SNPs caused by linkage disequilibrium (LD) 
and interaction effects [31]. Usually, individual effect 
sizes of SNPs are small, but collectively their impact on 
the phenotype can be substantial [32]. There are other 
weighty reasons for considering all genotyped SNPs 
simultaneously in analysis of GWAS. The predictive 
power of a single SNP is usually very low, but considering 
more disease relevant SNPs can improve the accuracy 
of prediction [33]. In the context of complex diseases 
multiple genes are involved in disease etiology, thus a 
joint analysis of multiple SNPs can be more informative 
and better reflect the relationship between genotype and 
phenotype than single SNP models [34].
A comprehensive overview of the advantages of 
model selection based approaches to analysis of GWAS is 
provided in Frommlet et al. 2016 [35], particularly addressing 
selection procedures based on modifications of the Bayesian 
information criterion (BIC) [36]. In high dimensional settings 
like GWAS where only a small number of SNPs is expected 
to be associated with disease (under sparsity), it has been 
shown repeatedly that BIC tends to select too large models. 
Various modifications of BIC have been proposed to solve 
this problem, among them mBIC2 [37, 38] which was 
designed to control the false discovery rate (FDR).
Here, we pursued a dual analysis strategy, reporting 
results from both single marker tests and MOSGWA [39], 
an implementation of a model selection procedure based 
on mBIC2. Genome-wide SNP data of 1060 CRC cases, 
689 patients with advanced colorectal adenomas and 4367 
controls were analyzed presenting the first GWAS of CRC 
in an Austrian population.
RESULTS
Downstream analysis was performed for 
492,217 SNPs using the software package MOSGWA. 
Additionally, results from single marker analysis via 
PLINK are reported using Cochran Armitage trend test 
(CAT) as well as univariate logistic regression models 
including the first four principle components as covariates 
to account for population structure.
Our study population consisted of four different 
case and control groups, CRC cases (A), advanced 
adenomas (B), colonoscopy-negative CORSA controls 
(C) and KORA controls (D) (Table 1). Further clinical 
characteristics of CRC cases and advanced adenomas are 
provided in Supplementary Table 1. Specifically, we report 
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the following four case-control comparisons: A vs. C, A 
vs. CD, AB vs. CD and B vs CD (Table 2).
Table 2 provides for each of the four comparisons some 
basic information and odds ratios for those SNPs corresponding 
to the model selected by MOSGWA. Additionally, P-values 
from CAT test, odds ratios, and P-values based on the 
univariate logistic model as well as the corresponding rank of 
each SNP according to the logistic model are presented. A list 
of the 200 top ranking SNPs for each contrast is provided in the 
Supplementary Materials (Supplementary Table 2).
A vs. C
For the comparison A vs. C, considering only Austrian 
cases and controls, MOSGWA selected a model of size three 
including SNPs rs1912804, rs9583269, and rs10495672. The 
best SNP rs1912804 has a marginal P-value of 3.39×10-7 that 
is not significant at the commonly adopted genome-wide 
significance level α=5.0×10-8. The three selected SNPs are 
among the top seven single marker SNPs (ranks 1, 2 and 7).
A vs. CD
Adding KORA controls increased power to detect 
associated SNPs. Accordingly, the comparison A vs. CD 
yielded a model containing seven SNPs including the top 
SNP rs17659990 (P=1.35×10-7; DOCK3).
AB vs. CD
For the joint analysis of CRC and advanced adenomas 
versus all controls, AB vs. CD, MOSGWA selected 14 SNPs, 
including rs17659990 (P=5.43×10-9, DOCK3) that reached 
the generally accepted level of genome-wide significance, 
followed by borderline significant rs7742915 (P=8.52×10-8, 
BTBD9), rs16944613 (P=1.49×10-7, CRTC3), rs13129679 
(P=2.38×10-7, RNF4) and rs12953717 (P=3.00×10-7, 
SMAD7), a well-known CRC susceptibility variant.
B vs. CD
For the comparison of advanced adenomas against 
the combined control (B vs. CD) MOSGWA identified one 
SNP on 11q14 (rs7944251, P=3.97×10-7, FAT3). Using only 
CORSA controls (B vs. C) there was not sufficient power 
to detect any SNP and MOSGWA selected the null model.
Genotype distributions of 56 CRC or colorectal 
adenoma susceptibility SNPs previously identified by 
GWAS were analyzed in the present genome-wide data 
set. Uncorrected P-values for all calculated case-control 
comparisons are provided in Table 3. For CRC SNPs, 
not covered by Axiom array, the distance of the proxy 
SNP from the original CRC SNP is provided in base 
pairs. P-values below 0.05 are given in bold, P-values 
below Bonferroni corrected significance level α=8.9×10-
4 are given in bold and are underlined. Several SNPs 
previously identified by CRC GWAS exhibit significantly 
different genotype distributions in cases and controls. 
The strongest associations were found for rs12953717 of 









and the RHPN2 SNP rs10411210 on 19q13.11 (P(Avs.
CD)=3.28×10
-4). Several SNPs of the well-known CRC 
susceptibility loci on chromosome 8 showed differentially 
distributed genotypes, among them rs16892766 on 8q23.3 
(P(Avs.CD)=5.48×10
-4, EIF3H), rs10505477 on 8q24.21 
(P(Avs.C)=6.08×10
-4, CASC8), and rs6983267 also located 
on 8q24.21 (P(Avs.C)=7.35×10
-4, MYC). Also rs3802842 on 
chromosome 11q23.1 showed significant associations with 





Several SNPs previously associated not only 
with risk of CRC but also with risk of colorectal 
adenoma exhibited borderline significant P-values 











Most published GWAS are based on single marker 
analysis in combination with correction for multiple 
Table 1: Study population
TotalPre-QC TotalPost-QC (%) Male (%) Female (%) Mean age ± SD [y]
CRC (A) 1060 978 (100.0) 584 (59.7) 394 (40.3) 63.5 ± 12.0
AA (B) 689 636 (100.0) 428 (67.3) 208 (32.7) 64.5 ± 10.3
ControlCORSA (C) 928 855 (100.0) 496 (58.0) 359 (42.0) 65.1 ± 11.8
ControlKORA (D) 3439 3439 (100.0) 1690 (49.1) 1749 (50.9) 53.8 ± 14.0
Total 6116 5908 3198 2710 58.2 ± 13.9
CRC Colorectal cancer cases.
AA Advanced adenomas.
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Table 2: Single marker tests and model selection
SNP Chromosome Gene OR (Logistic) P (Logistic) Rank 
(Logistic)
OR (Model) P (SM)
A vs. C (978 cases vs. 855 controls)
rs1912804 16q23.1 WWOX 1.69 3.39E-07 1 1.70 1.96E-07
rs9583269 13q33.3 MYO16 0.69 6.19E-07 2 0.69 1.24E-06
rs10495672 2p24.2 KCNS3 1.43 3.23E-06 7 1.46 1.95E-06
A vs. CD (978 cases vs. 4294 controls)
rs17659990 3p21.2 DOCK3 1.93 1.35E-07 1 1.98 1.59E-08
rs694339 18q22.3 CBLN2 1.97 1.41E-07 2 1.99 7.89E-07
rs12916300 15q13.1 HERC2 1.35 3.75E-07 4 1.35 1.37E-04
rs16845107 3q13.2 WDR52 0.52 5.94E-07 6 0.52 1.49E-06
rs11927424 3p11.1 C3orf38 1.31 1.17E-06 11 1.32 1.07E-07
rs16869961 4p15.31 KCNIP4 0.75 1.51E-06 13 0.74 1.25E-04
rs7774435 6p21.32 HLA-DQA2 - - - 1.46 3.52E-04
AB vs. CD (1614 cases vs. 4294 controls)
rs17659990 3p21.2 DOCK3 1.88 5.43E-09 1 1.96 2.94E-10
rs7742915 6p21.2 BTBD9 1.31 8.52E-08 2 1.32 1.44E-06
rs16944613 15q26.1 CRTC3 1.32 1.49E-07 4 1.31 3.71E-07
rs13129679 4p16.3 RNF4 2.30 2.38E-07 5 2.42 8.82E-07
rs12953717 18q21.1 SMAD7 1.26 3.00E-07 6 1.27 6.68E-08
rs742223 6p24.1 TMEM170B 0.60 5.47E-07 9 0.59 9.49E-08
rs2184857 1q43 CHRM3 0.79 7.10E-07 11 0.78 3.35E-09
rs4954585 2q22.1 CXCR4 1.26 9.84E-07 12 1.26 2.29E-08
rs7942260 11q21 PIWIL4 0.69 7.28E-06 30 0.67 1.84E-06
rs7221059 17q25.2 LINC00338 0.76 1.02E-05 45 0.74 2.92E-05
rs4361767 8p23.1 LOC157273 0.77 1.31E-05 62 0.75 6.91E-05
rs340145 3q13.2 TMPRSS7 0.82 3.91E-05 142 0.79 1.45E-04
rs7774435 6p21.32 HLA-DQA2 - - - 1.65 5.82E-05
rs3130954 6p21.33 HCG27 - - - 1.79 1.04E-04
B vs. CD (636 cases vs. 4294 controls)
rs7944251 11q14.3 FAT3 0.66 3.97E-07 2 0.66 1.27E-08
A  CRC cases (CORSA).
B  Advanced adenomas (CORSA).
C  Controls (CORSA).
D  Controls (KORA).
OR (Model) Odds ratio based on the coefficients of the model selected by MOSGWA.
P (SM) Single marker test P-value (Cochran Armitage trend test).
OR (Logistic) Odds ratio based on univariate logistic model.
P (Logistic) P-value of univariate logistic model.
Rank (Logistic) Rank of the SNP in the top SNP list of P (Logistic) sorted by P-value.
-  HLA region excluded from logistic models.
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testing, a strategy which has been shown to suffer both 
from unnecessarily low power and a relatively high risk 
of false positive detections in case of complex traits [38]. 
Reduced statistical power reflects one aspect of missing 
heritability in GWAS [1]. Simulation studies based on 
real SNP data provided evidence that model selection 
strategies may outperform multiple testing in detecting 
causal SNPs [39] while controlling the type I error rate 
of false detections and therefore, should be used to 
complement (standard) analysis of GWAS.
We performed – to our best knowledge – the first 
GWAS of CRC in an Austrian cohort including 1060 
CRC cases, 689 patients with advanced colorectal 
adenomas, 928 colonoscopy-negative controls, and 
additional genotype data of 3439 population-based 
KORA controls from southern Germany. Model selection 
analysis was based on MOSGWA [39], a bioinformatical 
tool for analysis of GWAS using the FDR controlling 
modification of BIC, mBIC2, which has been shown 
to have certain optimality properties with respect to the 
number of missclassifications. Due to its fixed selection 
criterion, MOSGWA requires no parameter tuning 
like LASSO-based approaches [40]. In simulation 
studies [39], MOSGWA exceeded the performance of 
competing approaches and when re-analyzing data of 
complex diseases from the Wellcome Trust Case-Control 
Consortium [41] several SNPs could be identified, which 
were not detected by other algorithms, but were later 
confirmed by independent studies [39].
In this study, MOSGWA selected models for 
different case-control comparisons, including between one 
and 14 SNPs. The theoretically well-founded advantage of 
the model selection approach is its larger power to detect 
candidate SNPs compared to single marker tests while 
at the same time strictly controlling the false discovery 
rate. Among all four studied contrasts, single marker tests 
yielded only one significant SNP (rs17659990, P=5.43×10-
9, DOCK3) at the usually recommended genome-wide 
significance level for the comparison AB vs. CD when 
considering the entire study population. Rs17659990 is 
an intronic variant of dedicator of cytokinesis 3 (DOCK3) 
gene, a gene specifically expressed in the central nervous 
system, that was associated with an attention deficit 
hyperactivity disorder-like phenotype [42]. DOCK3, 
also referred to as modifier of cell adhesion (MOCA), 
was also shown to be an inhibitor of Wnt/beta-catenin 
signaling [43], a pathway known to play an important 
role in colorectal carcinogenesis [44]. Moreover, multiple 
studies reported DOCK3 to be implicated in cancer cell 
invasion and migration (as recently reviewed [45]). The 
SNP rs17659990 was also included in the model A vs. CD 
(model size 7).
For the comparison AB vs. CD, MOSGWA 
selected a model including 14 SNPs, including apart 
from rs17659990 another borderline significant SNP 
(rs7742915, P=8.52×10-8, BTBD9). Rs7742915 of BTB 
domain containing 9 (BTBD9) gene, a locus encoding 
a BTB/POZ domain-containing protein, is involved in 
protein-protein interactions. Genetic variation of BTBD9 
was associated with susceptibility to Restless Legs 
Syndrome [46]. Aside from rs17659990 and rs7742915, 
further 12 variants with marginal P-values (P>5.0×10-
8) were selected for AB vs. CD comparison including 
rs16944613 (P=1.49×10-7, CRTC3), rs13129679 
(P=2.38×10-7, RNF4), and rs12953717 (P=3.00×10-7, 
SMAD7). Rs12953717 located in intron 3 of SMAD7 gene 
has been previously linked to CRC risk by two GWAS [5, 
9] and was subsequently confirmed as CRC susceptibility 
variant [47, 48] as recently discussed by Stolfi et al. [49]. 
SMAD7 is a negative regulator of transforming growth 
factor-β signaling. Depending on single marker tests only, 
SMAD7 rs12953717 may not have been regarded as a 
candidate SNP in our study.
Interestingly, rs1912804 of WW domain-containing 
oxidoreductase (WWOX) gene emerged in this study of 
CRC (A vs. C). Defects in this tumor suppressor gene were 
associated with multiple cancers [50] and altered WWOX 
expression was observed in tissues of CRC [51]. Recently, 
WWOX was shown to be involved in double-strand break 
repair [50]. Although defects in mismatch repair (MMR) 
genes influence both, hereditary and sporadic CRCs 
(recently reviewed [52]), no CRC risk SNPs annotating to 
MMR genes were identified by GWAS thus far.
In this study, we used model selection as a tool 
to detect SNPs associated with CRC, not aiming at 
the identification of a model which can be used later 
for prediction. Therefore, we do not provide model 
coefficients obtained by MOSGWA but only report the 
detected SNPs. This is crucial to understand the principle 
and function of model selection as tool for analysis 
of GWAS. Considering the identification of disease 
associated SNPs as a high-dimensional classification 
problem, SNPs can be classified as either associated or 
not associated with the trait. Theoretical results showed 
that performing model selection using the FDR controlling 
mBIC2 selection criterion yields a classification procedure 
which asymptotically minimizes the misclassification 
rate. The expected proportion of false positive SNPs is 
controlled at a level which decreases with sample size 
and which will be for this study below 5%. Therefore, 
about one or two false positive detections can be expected 
among the reported 14 SNPs in model AB vs. CD.
CRC SNPs identified by preceding GWAS were 
tested in a hypothesis-driven approach and a number 
of these SNPs exhibited relevant differences between 
cases and controls in our data set. Several risk variants 
were replicated in this study for the first time in the 
Austrian population. The strongest associations were 
observed for SNPs annotating to the following genes: 
SMAD7, RHPN2, EIF3H, CASC8, MYC, and COLCA1,2. 
Functional relevance was experimentally confirmed 
for only five common CRC risk loci [52]. Four of them 
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Table 3: Associations of CRC susceptibility SNPs identified by preceding GWAS
SNP Chr. Gene Ref. Distance P_AvC P_AvCD P_ABvC P_ABvCD P_BvC P_BvCD
rs10911251 1q25.3 LAMC1 23 3492 2.03E-01 5.59E-01 2.26E-01 6.08E-01 3.38E-01 8.03E-01
rs6687758 1q41 DUSP10 13 3769 2.40E-01 5.32E-01 4.24E-01 2.57E-01 8.29E-01 3.59E-01
rs6691170 1q41 DUSP10 13 265 2.29E-01 1.19E-01 3.96E-01 3.40E-01 9.64E-01 9.23E-01
rs2373859 2p22.1 SLC8A1 20 797 4.48E-01 9.68E-01 2.75E-01 8.66E-01 1.98E-01 5.54E-01
rs11903757 2q32.3 NABP1/SDPR 23 4909 7.26E-01 2.92E-01 9.02E-01 2.66E-01 5.29E-01 5.34E-01
rs10936599 3q26.2 TERC 13 8296 5.38E-01 8.38E-01 7.26E-01 9.83E-01 9.48E-01 5.98E-01
rs35509282 4q32.2 FSTL5 27 1030 9.40E-01 7.64E-01 9.20E-01 8.85E-01 9.35E-01 9.10E-01
rs275454 5p15.31 PAPD7 20 0 4.71E-01 2.87E-01 6.38E-01 5.04E-01 9.34E-01 9.80E-01
rs2853668 5p15.33 TERT 20 0 5.61E-01 8.88E-01 4.40E-01 8.84E-01 5.15E-01 8.38E-01
rs647161 5q31.1 PITX1/H2AFY 22 0 3.80E-03 6.79E-02 6.78E-03 8.45E-02 7.56E-02 3.31E-01
rs1321311 6p21.2 SRSF3/CDKN1A 19 1541 2.62E-01 9.68E-01 1.88E-01 7.48E-01 3.09E-01 5.60E-01
rs1525461 7q35 TPK1 20 3217 4.43E-01 5.59E-01 2.97E-01 2.87E-01 2.33E-01 1.84E-01
rs16888522 8q23.3 EIF3H 20 1580 8.15E-02 7.24E-02 2.27E-01 2.52E-01 9.43E-01 6.36E-01
rs16892766* 8q23.3 TRPS1/EIF3H/
UTP23
10 0 7.75E-03 5.48E-04 3.67E-02 3.23E-03 4.64E-01 5.74E-01
rs10505477 8q24.21 CASC8 25 0 6.08E-04 3.48E-03 5.44E-03 5.10E-02 3.38E-01 8.22E-01
rs10808555 8q24.21 CASC8, MYC 11 0 3.20E-03 2.08E-02 1.22E-02 1.28E-01 2.54E-01 9.78E-01
rs6983267* 8q24.21 CASC8, MYC 4 0 7.35E-04 3.03E-03 5.10E-03 4.36E-02 3.03E-01 9.34E-01
rs7014346 8q24.21 CASC8 9 0 2.31E-03 1.26E-02 4.42E-03 3.91E-02 9.48E-02 5.69E-01
rs7837328 8q24.21 CASC8 11 214 7.89E-03 9.95E-02 4.86E-03 1.43E-01 4.49E-02 6.62E-01
rs719725 9p24.1 TPD52L3/
UHRF2/GLDC
6 34073 3.07E-01 5.52E-01 2.16E-01 3.59E-01 2.57E-01 2.28E-01
rs10795668 10p14 KRT8P16/
TCEB1P3
10 0 3.26E-01 2.32E-01 1.56E-01 1.40E-01 1.65E-01 2.58E-01
rs704017 10q23.2 ZMIZ1-AS1 29 10425 6.97E-02 2.32E-02 1.65E-01 2.08E-01 9.04E-01 7.31E-01
rs1035209 10q24.2 ABCC2/MRP2 26 0 4.37E-01 5.15E-01 7.78E-01 9.56E-01 6.37E-01 4.96E-01
rs11196172 10q25.2 TCF7L2 29 224 8.12E-01 6.13E-01 5.86E-01 7.73E-01 2.26E-01 7.71E-01
rs12241008 10q25.2 VTI1A 28 513 3.40E-01 5.47E-01 6.91E-01 8.73E-01 4.73E-01 1.92E-01
rs1665650 10q26.2 HSPA12A 22 1647 8.07E-01 5.09E-01 5.57E-01 8.96E-01 3.95E-01 8.20E-01
rs1535 11q12.2 FADS2 29 7243 2.21E-01 2.31E-02 4.43E-01 3.77E-02 9.01E-01 4.78E-01
rs174550 11q12.2 FADS1 29 96 2.15E-01 2.18E-02 3.55E-01 3.99E-02 9.99E-01 4.17E-01
rs4246215 11q12.2 FEN1 17 5531 2.13E-01 3.07E-02 3.40E-01 5.52E-02 9.63E-01 4.76E-01
rs3824999 11q13.4 POLD3 19 1383 1.26E-01 2.32E-02 2.23E-01 5.58E-02 6.20E-01 4.41E-01
rs3802842* 11q23.1 COLCA1,2 7 0 8.98E-05 8.62E-05 1.11E-04 1.86E-05 4.85E-03 2.91E-03
rs10849432 12p13.31 CD9 29 1952 6.48E-01 7.73E-01 9.37E-01 3.89E-01 6.47E-01 2.32E-01
rs10774214 12p13.32 CCND2 22 1816 3.85E-02 4.02E-02 6.87E-02 3.68E-02 3.37E-01 4.48E-01
rs3217810 12p13.32 CCND2 23 887 4.27E-01 1.78E-01 2.74E-01 2.81E-02 2.94E-01 6.89E-02
rs3217901 12p13.32 CCND2 23 0 3.20E-01 3.11E-01 2.41E-01 2.18E-01 1.65E-01 3.00E-01
rs11169552 12q13.12 ATF1 13 0 5.08E-01 3.61E-01 2.72E-01 4.37E-02 2.05E-01 4.71E-02
rs7136702 12q13.12 LARP4/DIP2B 13 1753 7.08E-01 5.18E-01 5.40E-01 2.69E-01 3.91E-01 2.14E-01
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(rs16892766, EIF3H; rs6983267, MYC; rs3802842, 
COLCA2 and rs4939827, SMAD7) also play a role in our 
study population.
Sporadic CRCs usually arise from premalignant 
lesions (adenoma-carcinoma sequence), thus high-risk 
adenomas impact CRC risk [53, 54]. Removal of advanced 
adenomas during colonoscopy reduces mortality from 
CRC [55]. We included advanced colorectal adenomas 
into this study because these precursors are important 
targets for CRC prevention. Previously unreported 
rs7944251 of FAT tumor suppressor homolog 3 (FAT3) 
was associated with reduced risk of advanced adenoma 
(OR=0.66, P=3.97×10-7) and the SNP was also selected 
when comparing advanced adenomas with the combined 
control group (B vs. CD). All previously unreported 
candidate SNPs demand replication in independent CRC 
cohorts.
A strength of this study is the dual approach to 
analyze genotype distributions in a genome-wide SNP 
dataset including CRC cases, advanced adenomas and 
controls. CORSA controls (C) received a complete 
colonoscopy within B-PREDICT screening and were 
known to be free of colorectal polyps and CRC. 
Sometimes, these colonoscopy-negative controls are 
also referred to as “super-controls” [12]. A recent study 
indicated that exclusion of controls with a family history 
of CRC and of controls with record of colorectal adenomas 
can increase power [56]. To our knowledge, this is the 
first GWAS of CRC investigating Austrian CRC cases 
and premalignant colorectal tumors. However, limitations 
SNP Chr. Gene Ref. Distance P_AvC P_AvCD P_ABvC P_ABvCD P_BvC P_BvCD
rs59336 12q24.21 TBX3 23 1817 5.48E-01 6.78E-01 7.01E-01 7.19E-01 9.24E-01 7.89E-01








7 0 6.22E-01 3.63E-01 9.03E-01 5.40E-01 4.58E-01 7.19E-01
rs11632715 15q13.3 SCG5, GREM1, 
FMN1
16 989 5.01E-01 3.09E-01 3.03E-01 1.58E-01 2.61E-01 3.17E-01
rs16969681 15q13.3 SCG5, GREM1, 
FMN1
16 0 5.25E-01 2.82E-01 5.79E-01 2.46E-01 8.45E-01 3.70E-01
rs4779584 15q13.3 SCG5, GREM1, 
FMN1
7 0 7.37E-02 1.03E-02 8.98E-02 8.61E-03 2.63E-01 5.18E-02
rs9929218 16q22.1 CDH1/ZFP90 7 0 7.72E-01 4.05E-01 5.89E-01 8.57E-01 1.52E-01 1.06E-01
rs12603526 17p13.3 NXN 29 0 2.93E-01 1.85E-01 1.14E-01 4.43E-02 1.03E-01 6.63E-02
rs12953717 18q21.1 SMAD7 5 0 4.64E-04 2.83E-05 4.55E-04 8.64E-06 3.21E-02 5.04E-03
rs4464148 18q21.1 SMAD7 5 82 6.75E-02 1.80E-01 3.80E-02 1.11E-01 1.08E-01 3.22E-01
rs4939827* 18q21.1 SMAD7 7 0 8.37E-03 4.03E-04 9.92E-03 1.53E-04 1.31E-01 1.42E-02
rs7229639 18q21.1 SMAD7 25 170 2.69E-01 9.11E-02 1.36E-01 1.90E-02 1.96E-01 4.29E-02
rs10411210 19q13.11 RHPN2 7 0 3.94E-03 3.28E-04 2.07E-02 2.66E-03 4.64E-01 2.91E-01
rs2241714 19q13.2 TGFB1, B9D2 21 12506 6.30E-01 8.95E-01 6.57E-01 9.93E-01 8.08E-01 8.30E-01
rs2423279 20p12.3 BMP2/HAO1/
FERMT1
22 10815 8.46E-01 4.13E-01 7.65E-01 8.11E-01 3.03E-01 5.80E-01
rs4813802 20p12.3 BMP2/HAO1/
FERMT1
16 0 4.40E-02 3.49E-02 5.59E-02 1.88E-02 2.09E-01 1.48E-01
rs961253 20p12.3 BMP2/HAO1/
FERMT1
7 0 1.71E-01 1.12E-01 6.02E-01 4.29E-01 4.78E-01 3.46E-01
rs4925386 20q13.33 LAMA5 13 53263 9.93E-02 9.76E-02 1.25E-02 4.64E-03 7.60E-03 1.11E-03
P-values are uncorrected and P-values <0.05 (5.00E-02) are given in bold.
P-values <0.00089 (8.90E-04) are given in bold and are underlined.
Rs number followed by * indicates CRC SNP with experimentally confirmed functional relevance [52].
Oncotarget98630www.impactjournals.com/oncotarget
of the study are the limited sample size, especially in 
the subgroup of advanced adenomas as well as limited 
availability of environmental data of CRC cases impeding 
stratification analysis for environmental risk factors. To 
increase statistical power, individual level genotype data 
of additional controls (KORA) were included in the study. 
Because CORSA recruitment is ongoing, further Austrian 
CRC cases will be genotyped and integrated into the 
analysis to investigate population specific SNP signatures 
of CRC risk. Meta-analysis of GWAS present a powerful 
strategy to enhance the power of identifying weak 
genetic associations with disease phenotype, but is often 
complicated by between-study heterogeneity. Precision 
gained by combination of datasets may be spurious due to 
different study designs, divergent LD structures, different 
patterns of correlated phenotypes or dissimilar gene-
environment interactions across populations [57, 58].
The application of CRC SNP signatures to improve 
screening decisions is presently impeded by the fact that 
single risk variants account only for little heritability and 
thereby explain a small increment of risk. We hypothesize 
that potentially disease relevant variants not reaching genome-
wide significance may explain a substantial part of missing 
heritability and are worth exploration and follow-up. Also 
epigenetic alterations play an important role in colorectal 
carcinogenesis [59]. The combination of genetic and 
epigenetic biomarkers to a multi-marker panel considering 
also environmental risk factors could be suited to complement 
present screening strategies and for instance be applied after 
a positive fecal occult blood test, but prior to an invasive 
colonoscopy. Genetic risk variants are ideal candidates for 
the development of minimal-invasive and cost-effective 
biomarker tests enabling personal risk profiling. In the near 
future, management of CRC will increasingly focus on 
personalized screening and treatment strategies aiming at early 
detection and prevention of disease. A combination of single 
marker tests and model selection in high dimensions may 
facilitate the identification of marker candidates otherwise 
not detected due to stringent penalties for multiple testing.
MATERIALS AND METHODS
Study population
In this GWAS, 2677 individuals of our ongoing 
Colorectal Cancer Study of Austria (CORSA) [60, 61] 
were genotyped including 1060 CRC cases, 689 patients 
with advanced adenomas and 928 colonoscopy-negative 
controls. CRC cases were patients with histologically 
confirmed, sporadic CRC. CRC cases with clinical record 
of inflammatory bowel disease (IBD) were excluded from 
the study. Advanced adenomas included adenomatous 
villous, adenomatous tubulovillous and tubular polyps 
larger than 1cm in diameter. All controls received a 
complete colonoscopy and exhibited no pathological 
findings.
From June 2003 to November 2012 CORSA 
participants had been recruited in four hospitals in the 
province Burgenland (Oberpullendorf, Kittsee, Oberwart 
and Güssing), Austria, at the Medical University of Vienna 
(Department of Surgery), and the Medical University of 
Graz (Department of Internal Medicine).
To augment statistical power, individual level 
genotype data of 3439 additional control individuals from 
the German “Cooperative Health Research in the Region 
of Augsburg” (KORA) platform were included in this 
study [62]. Population-based controls from the studies S4 
and F4 were integrated. To ensure exclusion of CRC cases 
from the KORA control set, all individuals with evidence 
of malignant diseases were removed from the dataset. In 
total, 6116 individuals (1749 colorectal tumors and 4367 
controls) were included in this study.
Ethics statement
Written informed consent was obtained from 
all participants of CORSA. The study was approved 
by the ethical review committee of the Medical 
University of Vienna (MUW, EK Nr. 703/2010) and the 
“Ethikkommission Burgenland” (KRAGES, 33/2010). 
Conduct of the study followed the approved study protocol 
and all methods were performed in accordance with the 
relevant guidelines and regulations. Approval for the use 
of KORA data was obtained from the KORA-Study Group 
(K072/13).
Genotyping
Genomic DNA was purified from peripheral blood 
following the QIAamp DNA Blood Midi Spin Protocol 
(QIAGEN, Valencia, CA). Genotyping was performed 
using population-optimized Axiom Genome-Wide CEU 1 
Arrays (Affymetrix, Santa Clara, CA) analyzing 587,532 
SNPs. Array processing was performed at the Institute 
of Human Genetics, Helmholtz Center Munich. KORA 
samples were genotyped on the same array type.
Statistical analysis
Extensive quality control and genotype calling was 
performed with Affymetrix Genotyping Console Software 
4.1.3.840 (www.affymetrix.com). 2469 genotyped 
CORSA subjects survived QC filtering (Dish QC >0.82, 
call rate >97.5%).
Inclusion criteria for SNPs eligible for downstream 
analysis were a minor allele frequency (MAF) >1%, 
Hardy-Weinberg equilibrium (HWE) P-value cut-off 
>1.00×10-8, a SNP call rate >97.5%, and >95% calls per 
individual. 271 SNPs were discarded due to showing 
significant difference between the CORSA and KORA 
control group (P-values smaller than 1.00×10-7 in a simple 
Fisher exact test comparing controls as suggested in 
[63]). After filtering, 492,217 SNPs remained for which 
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imputation of missing genotypes was performed using 
Beagle software v.4.0 r1274 [64].
The primary aim of the study was to find SNPs which 
are associated with CRC or with advanced adenomas, 
respectively. To this end we performed traditional single 
marker based analysis as well as a more involved model 
selection based approach. Single marker analysis was 
performed with PLINK 1.9 beta 3 (www.cog-genomics.
org/plink2) [65]. We report P-values of CAT as well as 
from a logistic regression model including the factors age 
and the leading four principal components from a principal 
component analysis (PCA) which was used to adjust for 
population structure [66]. A PCA plot of the first four 
principal components plotted against each other is provided 
in Supplementary Figure 1. Genotype cluster plots of all 
reported SNPs underwent visual inspection.
For model selection analysis, the software package 
MOSGWA was applied (http://mosgwa.sourceforge.
net) [39] using multi-marker logistic regression models 
including again the factors age and the leading four 
principal components as covariates which were not under 
selection. In addition to the genome-wide analysis we 
inspected specifically 56 SNPs which were previously 
reported in the GWAS literature to be involved in 
colorectal carcinogenesis. For SNPs not represented on 
the array, suitable proxies were identified and tested.
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